Here's How I'd Invest $10,000 Right Now

The article recommends a hypothetical $10,000 portfolio split of $6,000 into Enbridge, $3,000 into Alphabet, and $1,000 into CRISPR Therapeutics. It highlights Enbridge's roughly 5% yield and 16% YTD gain, Alphabet's $160 billion in profit over the past four quarters, and CRISPR's $2 billion-plus cash position plus approved gene-editing therapy Casgevy. The piece is largely a stock-picking commentary rather than new company-specific news, so market impact should be limited.

Analysis

The portfolio construction message is directionally right, but the real signal is factor mix: the proposed basket is a low-volatility cash-yield anchor, a mega-cap compounding engine, and a high-upside biotech call option. That combination is effectively a barbell between durable cash generation and idiosyncratic innovation, which should outperform a purely “quality growth” basket if rates stay elevated and dispersion across sectors remains wide. The underappreciated benefit is that ENB’s defensive cash flows can finance patience in CRSP, where the equity can remain dead money for long stretches before binary re-rating events.

Relative winners are the capital-return and infrastructure businesses: if investors keep rewarding visible cash yields over duration-heavy assets, ENB’s funding-cost discipline and buyback-free dividend profile should continue to screen well versus more levered energy names. GOOGL benefits from the market treating it as “ETF-like” diversification in one ticker, but the market may still be underestimating how much AI spend can be absorbed by operating leverage if Search and YouTube remain stable; the risk is not fundamental collapse but multiple compression if ad growth normalizes while capex stays high. CRSP is the most asymmetric leg because the market will likely price commercialization on a rolling milestone basis rather than on near-term earnings, making each quarterly update a volatility event.

The contrarian view is that this is not a particularly brave growth pick: GOOGL is consensus-quality, ENB is consensus-defensive, and CRSP is the only real risk, so the basket may be less innovative than it appears. The market may also be overpaying for “safe” yield in midstream if commodity sentiment cools; ENB’s lower beta can disguise duration risk if rates re-steepen. For CRSP, the big miss is that approved therapy does not automatically translate into a durable platform rerating; commercialization friction, pricing pressure, or slower-than-expected patient uptake could keep the equity range-bound for 12-18 months despite headline progress.

Key Decisions for Investors

• Long ENB as a defensive carry trade for the next 6-12 months; target the dividend plus low-single-digit price appreciation, but reduce if rates move higher and midstream multiple expansion stalls.
• Long GOOGL on any post-earnings pullback; this is a quality-growth compounder with downside cushioned by balance sheet strength, but trim if capex-to-revenue rises without a corresponding acceleration in cloud/ad growth.
• Treat CRSP as a call option, not a core holding: buy only small size ahead of commercialization milestones over the next 3-9 months, with a hard risk budget of <=1% portfolio NAV.
• Pair trade idea: long GOOGL / short a basket of higher-duration AI beneficiaries with weaker cash flow visibility; the spread should favor balance-sheet quality if the market de-rates speculative growth over the next quarter.
• If building this basket, finance CRSP with a smaller ENB or GOOGL trim rather than adding new capital; the risk/reward is best when the biotech leg is funded by realized cash yield, not incremental leverage.